Can Fite Biopharma Ltd ADR

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company based in Ramat Gan, Israel, that develops orally bioavailable small molecule therapeutics for cancer, liver inflammatory diseases, and erectile dysfunction. Its lead drug candidate, Piclidenoson, has completed a Phase III clinical trial for psoriasis. Namodenoson is in Phase III for liver cancer, Phase IIa for pancreatic cancer, and Phase IIb for metabolic associated steatohepatitis, while CF602 is in pre-clinical trials for erectile dysfunction. The company also offers cannabinoids for conditions associated with elevated A3 adenosine receptor expression and is developing a commercial predictive biomarker blood test kit for A3AR. It has a license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. Formerly Can-Fite Technologies Ltd., it changed its name to Can-Fite BioPharma Ltd. in January 2001, was incorporated in 1994, and is headquartered in Ramat Gan, Israel.